Cells is under clinical development by ICamuno Biotherapeutics and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 73% phase transition ...
Unmodified natural killer (NK) cells work differently from the T-cells upon which CAR-T therapies are based – NKs are usually involved in killing cells that are infected with viruses, whereas T ...
In laboratory experiments, doctoral students Tobias Bexte and Nawid Albinger succeeded in completely switching off an important immune checkpoint in NK cells that were specifically directed ...
Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer and infectious diseases, today announced an ag ...